November 08, 2021
Article
Year-long treatment with the biologic resulted in significant improvements in patient perception of well-being and treatment effect.
November 05, 2021
Data from the LIBERTY AD ADOL trial showed that adolescent patients with moderate-to-severe atopic dermatitis treated with the biologic reported decreases in total and allergen-specific IgE levels for cat dander, peanuts, and more.
Over half of all patients in the study had achieved an EASI-75 within a year, and investigators noted that patient and family satisfaction with the MADP program was high.
November 14, 2019
For what other indications, and in what regimens, are investigators assessing the drug class?
November 13, 2019
Certain diet-based comorbid conditions are more prevalent in food-allergic patients.
November 12, 2019
At least 1 major food allergy trial in recent years has given allergists incentive to set detailed strategies for their patients.
Could the drug class best serve patients as an adjunctive, a monotherapy, or maybe a prophylaxis for symptoms?
November 11, 2019
Though research behind preventive measures is lacking, there are common steps that could be taken to reduce pediatric risk.
As new methods of treatment come to the market, allergists need to ensure their patients are fully informed and able to set their own goals for care.
November 10, 2019
Video
How can physicians train parents to trust immunotherapy—an allergen exposure they were previously told to avoid?
Charles Wykoff, MD: Shifting the Treatment Paradigm with Pegcetacoplan for GA
Peter J Kertes, MD: Insights into the TALON Trial on Brolucizumab Versus Aflibercept
Initially Costlier, Ranibizumab PDS May Be More Cost-Effective Long-Term for nAMD Patients
